851895-20-0

Usage

Uses

Used in Medicinal Chemistry:
(4-ethynylphenyl)(morpholino)methanone is utilized as a versatile intermediate in medicinal chemistry for the synthesis of a range of pharmacologically active compounds. Its unique molecular structure allows for the development of new drugs with potential therapeutic applications.
Used in Drug Discovery:
In the field of drug discovery, (4-ethynylphenyl)(morpholino)methanone serves as a potentially useful building block. Its incorporation into the molecular frameworks of new compounds can lead to the discovery of novel therapeutic agents with improved efficacy and selectivity.
It is crucial to handle (4-ethynylphenyl)(morpholino)methanone with care and adhere to all safety guidelines to mitigate any potential health hazards associated with its use.

Upstream product

• 110-91-8 morpholine 
• 10602-00-3 4-Ethynyl-benzoic acid 
• 127580-92-1 (4-bromophenyl)(morpholino)methanone 
• 851895-19-7 morpholin-4-yl-(4-trimethylsilanylethynyl-phenyl)-methanone 

Downstream Products

• 736991-26-7 C₁₉H₂₆BNO₄ 

Relevant academic research and scientific papers

Asymmetric Synthesis of Silicon-Stereogenic Vinylhydrosilanes by Cobalt-Catalyzed Regio- and Enantioselective Alkyne Hydrosilylation with Dihydrosilanes

The strategic carbon-to-silicon substitution at a stereogenic center can produce chiral silanes with significantly improved properties relative to their carbon congeners. We herein report an unprecedented cobalt-catalyzed asymmetric hydrosilylation of unsymmetric alkynes with dihydrosilanes that furnishes silicon-stereogenic vinylhydrosilanes with high regio- and enantioselectivity. The absolute configurations of the products were determined by chiroptical methods in combination with DFT calculations. The synthetic versatility of the vinylhydrosilanes as chiral building blocks was further demonstrated by asymmetric Si?H insertion and catalytic hydroboration reactions.

Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity

Pyrrolo-pyrimidones of the general structure 1 were synthesized and evaluated for their potential as MK2 inhibitors. Potent derivatives were discovered which inhibit MK2 in the nanomolar range and show potent inhibition of cytokine release from LPS-stimul

BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R6, A and Y are as defined in the specification, as inhibitors of (MK2 or MAPKAP kinase-2).

Benzodioxepine derivatives

This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACCβ inhibitors.

BENZO [b][1,4] DIOXEPINE DERIVATIVES

This invention relates to compounds of the formula (I), wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACCβ inhibitors.